Monitor for definitive Molteni agreement and any financing announcements given limited cash runway into H2 2026. Stock likely to remain range-bound absent catalysts.
Price Chart
Executive Summary
Adial Pharmaceuticals reported Q1 2026 results with net loss improving to $2.0M from $2.2M YoY, driven by lower R&D spending. Cash stood at $4.6M, funding operations into H2 2026. The company highlighted regulatory progress and a collaboration framework with Molteni, but no definitive agreement or material financial catalysts emerged.
Key Facts
- Net loss narrowed to $2.0M for Q1 2026 vs $2.2M in Q1 2025
- Cash and cash equivalents $4.6M as of March 31, 2026
- R&D expenses decreased 42% to $433K due to reduced clinical activity
- G&A expenses increased 3% to $1.6M
- Company is pre-revenue, with no product sales
- Collaboration framework with Molteni for European commercialization of AD04, potential $60M deal
- Cash runway expected into H2 2026
Financial Impact
Net loss improved $0.2M YoY; cash burn rate ~$2M/quarter
Risk Factors
- Cash runway only into H2 2026; potential dilutive financing
- No approved products; clinical trial and regulatory risks
- Partnership with Molteni not yet definitive
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-054219 |
| Document: ea028994701ex99-1.htm | 0001213900-26-054219 |
| Document: 0001213900-26-054219-index-headers.html | 0001213900-26-054219 |
| Document: 0001213900-26-054219-index.html | 0001213900-26-054219 |
| Document: 0001213900-26-054219.txt | 0001213900-26-054219 |
| 8-K Data (Synthetic) | 0001213900-26-054219 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | EFFECT | $3.68 | awaiting T+60 | — | $3.71 (−0.82%) |
Oct 20, 2026 7d ago | 10-Q/A | $4.11 | awaiting T+60 | — | $3.71 (+9.73%) |
Oct 20, 2026 7d ago | S-3/A | $4.11 | awaiting T+60 | — | $3.71 (+9.73%) |
Oct 16, 2026 11d ago | DEFA14A | $3.62 | awaiting T+60 | — | $3.71 (−2.49%) |
Oct 16, 2026 11d ago | 8-K | $3.62 | awaiting T+60 | — | $3.71 (−2.49%) |
Sep 30, 2026 27d ago | Press Release | $4.13 | awaiting T+60 | — | $3.71 (−10.17%) |
Sep 18, 2026 5w ago | DEFA14A | $4.40 | awaiting T+60 | — | $3.71 (−15.68%) |
Sep 18, 2026 5w ago | 8-K | $4.40 | awaiting T+60 | — | $3.71 (−15.68%) |
Sep 16, 2026 5w ago | DEFA14A | $5.21 | awaiting T+60 | — | $3.71 (−28.79%) |
Sep 16, 2026 5w ago | 8-K | $5.21 | awaiting T+60 | — | $3.71 (−28.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers